Objectives: Genotype–phenotype correlation in congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency ranges from 45 to 97 %. We performed massively parallel sequencing of CYP21A2 on stored newborn bloodspot samples to catalogue the genotypes present in our patients with CAH and enable genotype–phenotype comparison. Methods: Participants ≤15 years old with clinically diagnosed CAH were recruited from The Sydney Children’s Hospitals Network. Phenotype was classified from clinical and biochemical details in the medical record as salt wasting (SW), simple virilising (SV), non-classic (NC) or an intermediate phenotype (SW/SV; SV/NC). Amplicon-based sequencing for CYP21A2 was performed on stored newborn bloodspot samples by the New South Wales Newborn Bloodspot Screening Laboratory on MiSeq™Dx (Illumina, California). Available genetic test results were also obtained from the medical records. Results: Samples from 67 participants (43 % female, age 0.3–15 years) were sequenced, including 9 sibships. SW phenotype was present in 33/67 participants (49 %), SV in 9 (13 %) and NC in 16 (24 %). Intermediate phenotypes included SW/SV in seven participants (10 %) and SV/NC in two (3 %). Variants were identified in 90/116 alleles (78 %). A complete genotype was available in 47/67 participants (70 %). The most common genotype was homozygous c.293-13A/C>G (I2G) in 7/47 participants (15 %). Genotype correlated with the most commonly reported phenotype in 36/44 cases (82 %). Correlation was higher in SW and NC phenotypes. Conclusions: This study uses genetic testing of newborn bloodspots to identify and characterise the genotypes present in an ethnically diverse Australian population with CAH. It further strengthens our knowledge of genotype–phenotype correlations in CAH.
8 November 2024 in The Journal of Clinical Endocrinology & Metabolism
Context Up to 20% of patients with X-linked hypophosphatemic rickets (XLH) have no causative variant identified on routine molecular diagnostic testing. Objective To identify intronic variants causing PHEX mis-splicing in patients with XLH. Setting The metabolic bone clinic of a paediatric orthopedic hospital. Participants Four patients (age 6 to 12 years; 3 girls) with clinically diagnosed XLH and no PHEX variant on routine testing. Main outcome measures RNA and DNA sequence analysis of PHEX. Methods Urine-derived cells were cultured, and mRNA was extracted and transcribed to cDNA. PHEX cDNA was amplified by PCR, followed by sequencing of PCR products. Sequencing of PHEX intronic DNA regions was performed to identify variants causing mis-splicing observed on RNA analysis. Results PHEX mis-splicing was identified in 3 of the 4 participants, and an intronic variant was identified in all 3 cases. In a 12-year-old boy, transcript analysis showed skipping of PHEX exon 13, while sequencing of PHEX intronic regions revealed a de novo 18 bp deletion in intron 13. In a 7-year-old girl, a pseudoexon in PHEX intron 17 was found, associated with a de novo deep intronic variant (c.1768+173A>G) that activated a cryptic splice donor site. Finally, an 84 bp pseudoexon in PHEX intron 21 caused by a recurrent de novo deep intronic variant (c.2147+1197A>G) was identified in an 11-year-old girl. Conclusions Analysis of RNA from urine-derived cells combined with sequencing of PHEX introns can identify deep intronic variants in individuals with XLH without a detectable PHEX variant in routine exon-centric molecular diagnosis.
Denosumab, a monoclonal antibody against receptor activator of NF-κB ligand, is frequently used to manage hypercalcemia and has recently been recommended as first-line therapy in adults with hypercalcemia of malignancy. Despite this, its use in the pediatric population is not well described for this indication. Our case series illustrates a multicenter experience using denosumab in the management of acute and chronic hypercalcemia. Patients had an age range of 2 mo to 16 yr of age. They had varying causes of hypercalcemia, including hypercalcemia of malignancy, the ketogenic diet, and Williams syndrome. Peak hypercalcemia ranged from 3.29 to 5.04 mmol/L and treatments trialed included intravenous fluids, calcitonin, and glucocorticoids. All patients received multiple doses of denosumab, with an individual dose range of 0.125-0.5 mg/kg, which successfully improved hypercalcemia. In two patients, denosumab was used as bridging therapy until acute renal impairment improved before giving bisphosphonates. Two patients experienced mild hypocalcemia which was managed with oral supplementation. Denosumab may be considered in the management of hypercalcemia, where other treatment has not been effective or where there is concomitant renal impairment and bisphosphonate therapy is contraindicated. Multiple doses of denosumab may be required and children must have their serum calcium monitored closely during therapy.
30 October 2025 in European Journal of Endocrinology
Objective: Denosumab, a potent antiresorptive agent targeting receptor activator of nuclear factor kappa-B ligand (RANKL), is increasingly used off-label in RANKL-mediated pediatric bone disorders, but concerns remain regarding rebound hypercalcemia and altered bone modeling and remodeling. This study describes clinical, biochemical, and radiological features of metaphyseal sclerotic band fractures in children on denosumab and assesses risk factors with focus on timing and occurrence of rebound hypercalcemia. Design and Methods: We conducted a retrospective multicenter study. Clinical, biochemical, and X-ray data were reviewed. High-resolution peripheral quantitative computed tomography (HR-pQCT) and micro-finite element analysis were performed in 1 case to assess bone microarchitecture. Results: Five pediatric patients (aged 7-18 years) were included: 4 received denosumab for RANKL-mediated bone lesions, and 1 for secondary osteoporosis. Fractures occurred 1.5-7.7 years after starting denosumab, involving the distal radius, ulna, femur, clavicle, and rib. All followed low- or moderate-impact trauma and involved zones of metaphyseal sclerosis. Rebound hypercalcemia occurred in all patients (1 to >16 episodes); in 4 cases, it preceded the fracture by 0-4 months, while 1 case first developed hypercalcemia 3 weeks postfracture. HR-pQCT in a single patient revealed markedly increased trabecular volumetric bone mineral density and stiffness within the sclerotic band plus reduced estimated failure load. Bisphosphonates were used, albeit variably, for prevention or treatment of hypercalcemia. Conclusions and Relevance: Fractures through sclerotic metaphyseal bands may represent a distinct complication of denosumab therapy in children. Rebound hypercalcemia and fractures can co-occur, underscoring the need for close monitoring and management by pediatric bone specialists throughout treatment.